Aggarwal, Vaishali http://orcid.org/0000-0001-7964-3479
Workman, Creg J. http://orcid.org/0000-0002-9964-9509
Vignali, Dario A. A. http://orcid.org/0000-0002-2771-5992
Article History
Received: 5 December 2022
Accepted: 19 June 2023
First Online: 24 July 2023
Competing interests
: D.A.A.V. and C.J.W. declare patents covering LAG-3, with others pending, and are entitled to a share in net income generated from licensing of these patent rights for commercial development. D.A.A.V. is a cofounder and stock holder of Novasenta, Potenza, Tizona and Trishula and a stock holder of Oncorus and Werewolf; has patents licensed and royalties in BMS and Novasenta; is a scientific advisory board member of Tizona, Werewolf, F-Star, Bicara, Apeximmune and T7/Imreg Bio; is a consultant for BMS, Incyte, Regeneron, Ono Pharma and Avidity Partners; and receives research funding from BMS and Novasenta. The other authors declare no competing interests.